Insmed is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases and protein-based therapeutics.
On December 1, 2010 Insmed, Inc. and Transave, Inc. combined to create a biopharmaceutical company with near-term commercial opportunities. For more information, please see the press release dated December 2, 2010 in our newsroom.